Table 3.
The programming of FET following ICSI treatment in freeze-all cycles
| OPU | Days of blastocyst vitrification | OCP | OCP wash-out | Endometrial preparation |
E
6 mg P 8% × 2 |
FET | |||||
|
E
2 mg |
E
6 mg |
E
8 mg |
Day 14
X ET X P |
||||||||
| The number of days | 1 | 6 | 7 | 10–30 | 35–40 | 41–44 | 45–48 | 48 | 49–54 | 54 | |
| OPU | Days of blastocyst vitrification | Downregulation period | Endometrial preparation |
E
6 mg P 8% × 2 |
FET | ||||||
|
Lucrin
depot |
E
2 mg |
E
6 mg |
E
8 mg |
Day 14
X ET X P |
|||||||
| The number of days | 1 | 6 | 7 | 17–22 | 23–26 | 27–30 | 30 | 31–36 | 36 | ||
OPU oocyte pickup, FET frozen embryo transfer, E estrogen supplementation (2 mg, Estrofem, Novo Nordisk, Istanbul, Turkey), P progesterone supplementation (8 %, Crinone, Merck Serono, Turkey), OCP oral contraceptive pill (Ginera®, Bayer, Istanbul, Turkey) for at least 21 days
Vitrification; blastocyst vitrification using the Cryotop method
Lucrin depot; ½ dose (3.75 mg, Leuprorelin acetate, Abbott, Mumbai, India) bolus injection
X ET, TVUS to measure endometrial thickness, with >6 mm preferred
X P, Progesterone blood concentration, with <2 ng/mL preferred